查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1992763

进行性及復发性卵巢癌市场：依治疗方法、给药途径、治疗线、生物标记状态及最终用户划分－2026-2032年全球市场预测

Advanced Recurrent Ovarian Cancer Market by Treatment Type, Administration Route, Line Of Therapy, Biomarker Status, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，进行性復发性卵巢癌市值为 16.8 亿美元，预计到 2026 年将成长至 18.5 亿美元，复合年增长率为 9.69%，到 2032 年将达到 32.2 亿美元。

主要市场统计数据
基准年 2025 16.8亿美元
预计年份：2026年 18.5亿美元
预测年份 2032 32.2亿美元
复合年增长率 (%) 9.69%

观点不断变化的临床、监管和商业性环境，为进行性和復发性卵巢癌的相关人员提供策略决策框架。

进行性和復发性卵巢癌的治疗和商业格局瞬息万变，临床范式不断转变，相关人员的关注度也日益提高。本执行摘要介绍了本研究的核心主题，重点阐述了标靶治疗、生物标记主导的治疗以及医疗服务模式的进步如何融合，从而改变復发性患者的治疗路径。此外，本概要还概述了监管压力、支付方期望以及供应链的考量，这些因素共同影响临床进展并最终决定商业性可行性。

先进的诊断技术、不断发展的给药途径以及支付方主导的证据要求，正在如何重塑治疗模式和商业化策略？

由于治疗方法的创新、诊断技术的精准化以及医疗服务体系的重塑，进行性和復发性卵巢癌的治疗模式正在发生变革性变化。新型标靶治疗疗法和联合治疗正在重新定义疗效预期与耐受性之间的权衡，而伴随诊断和同源重组缺陷（HRD）检测的广泛应用则使得个人化治疗方法方案成为可能。因此，传统的化疗为中心的治疗路径正在调整，优先考虑在分子层面上明确标标靶药物和免疫疗法联合治疗。

2025 年贸易政策转变对癌症治疗供应链韧性、采购惯例和市场定位的策略影响。

2025年关税的实施和贸易政策的转变为进行性和復发性卵巢癌生态系统中的相关人员带来了显着的营运和策略复杂性。供应链经理和采购团队正在透过审查其原料药、成品和关键诊断剂的筹资策略来应对这些挑战，以降低成本波动和交货延迟的风险。因此，拥有垂直整合供应链和多元化製造地的公司能够更柔软性应对关税的短期影响，而其他公司则正在加快供应商合格和紧急时应对计画。

从综合细分观点来看，治疗分类、给药途径、治疗线、生物标记定义的队列、医疗保健环境和分销管道如何相互作用，从而影响采用趋势。

细分市场分析揭示了治疗决策、给药途径选择、在治疗体系中的定位、生物标记状态、医疗机构以及分销合作伙伴如何相互交织，共同塑造临床和商业性发展轨迹。根据治疗类型，市场涵盖化疗（包括含铂类药物和非含铂类药物） 、荷尔蒙疗法疗法（包括Aromatase抑制剂和雌激素受体调节） 、免疫疗法（包括癌症疫苗和查核点抑制剂）、手术（作为关键干预手段）以及标靶治疗（包括抗血管新生药物和PARP抑制剂）。每类药物都有其独特的疗效特征、耐受性考量以及影响临床应用所需的实证医学证据。

差异化的打入市场策略受到区域挑战以及世界各地不同地区支付方的多样性、诊断能力和监管差异的影响。

区域趋势对临床路径、监管预期、诊断方法应用和商业化策略有显着影响。在美洲，支付方的多样性和集中化的专科药房网络凸显了卫​​生经济学证据和病患支持计画对于确保医保覆盖和就医便利的重要性。在欧洲、中东和非洲（EMEA），不同的法规环境和报销框架要求制定符合各国支付方标准和区域医疗环境的打入市场策略。同时，各地区诊断基础设施和分子检测的可近性也存在显着差异。在亚太地区，部分国家诊断能力的快速扩张和癌症治疗公共投入的增加为早期市场准入创造了机会，但当地的监管和定价压力往往要求企业采用适应性强的商业化模式。

透过临床差异化、诊断伙伴关係和策略联盟来塑造竞争定位，可以精准定位患者并与支付方建立联繫。

在进行性復发性卵巢癌领域，竞争格局主要集中在跨国製药公司、专注于肿瘤生物技术的公司、提供基于生物标记疗法的诊断公司以及新兴的契约製造和分销合作伙伴之间。主要企业透过设计强调有意义的无恶化生存期和患者报告结局的临床项目、推进基于生物标誌物的适应症拓展以及投资伴随诊断来锁定特定患者群体，从而脱颖而出。创新生物技术公司经常致力于联合治疗和新型作用机制的研发，以克服抗药性问题，而老字型大小企业则利用其规模、商业基础设施和全球监管经验来加速产品上市。

产业领导者可以采取切实可行的策略步骤来整合诊断、增强证据产生、加强供应链并加快跨市场保险公司的接受度。

产业领导者应优先采取一系列切实可行的步骤，以掌握治疗和商业性机会，同时降低风险。首先，将生物标记策略整合到临床开发的各个阶段，从最初的人体试验到扩大适应症的试验，以确保及时获得伴随诊断和明确的患者选择标准。其次，儘早投资于真实世界数据 (RWE) 的生成和卫生经济学研究，以支持与保险公司的对话，并展现超越传统疗效终点的后续价值。第三，设计开发方案时，应将给药途径作为商业性差异化因素，并在临床可行的情况下评估口服和皮下製剂，以支持门诊治疗和提高用药依从性。

为了确保实用性，我们采用透明的混合方法研究方法，结合了专家的直接知识、对二手资讯的严格检验以及情境分析。

本报告的调查方法整合了对临床专家、支付方和商业化负责人的定性访谈、对同行评审期刊和监管文件的文献综述，以及对诊断和治疗产品线的结构化整合。主要资讯包括对肿瘤科临床医生、医院药剂师和市场准入专家的半结构化访谈，旨在检验临床路径、识别推广障碍并提取支付方重视的证据重点。次要研究着重于监管指导文件、临床试验註册数据和已发表的结果研究，以支持治疗的疗效、安全性和诊断效用。

强调诊断主导的个人化、实证发展和供应链韧性的综合洞察是永续商业性成功的关键支柱。

总之，进行性和復发性卵巢癌的生态系统正处于一个十字路口，诊断主导的个体化治疗、治疗创新和支付主导的证据需求在此交汇，势必重塑临床和商业性路径。积极整合生物标记策略、优先考虑符合支付方需求的证据产生、并优化以患者为中心的给药方案的相关人员将获得竞争优势。此外，供应链设计的韧性和区域性调适策略对于应对政策相关的成本压力和不同的区域报销环境至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法进行性和復发性卵巢癌市场

  • 化疗
    • 非含铂类药物
    • 含铂类药物
  • 荷尔蒙疗法
    • Aromatase抑制剂
    • 雌激素受体调节
  • 免疫疗法
    • 癌症疫苗
    • 查核点抑制剂
  • 外科手术
  • 分子标靶治疗
    • 抗血管新生药物
    • PARP抑制剂

第九章：按给药途径分類的进行性和復发性卵巢癌市场

  • 腹腔内
  • 静脉
  • 口服
  • 皮下

第十章：依治疗阶段进行性和復发性卵巢癌市场

  • 从第四行开始
  • 第二行
  • 第三行

第十一章：按生物标记状态进行性和復发性卵巢癌市场

  • 同源重组缺陷阴性
  • 同源重组缺陷阳性

第十二章：进行性和復发性卵巢癌市场：按最终用户划分

  • 门诊部
  • 癌症中心
  • 医院
  • 专科诊所

第十三章：进行性和復发性卵巢癌市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：进行性和復发性卵巢癌市场：按组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：进行性和復发性卵巢癌市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国进行性和復发性卵巢癌市场

第十七章：中国进行性及復发性卵巢癌市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celsion Corporation
  • Clovis Oncology Inc.
  • Debiopharm International SA
  • Eli Lilly and Company
  • Exelixis Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline plc
  • ImmunoGen Inc.
  • Johnson & Johnson Services, Inc.
  • Kintara Therapeutics Inc.
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vivesto AB
Product Code: MRR-1A1A064BFFBB

The Advanced Recurrent Ovarian Cancer Market was valued at USD 1.68 billion in 2025 and is projected to grow to USD 1.85 billion in 2026, with a CAGR of 9.69%, reaching USD 3.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.68 billion
Estimated Year [2026] USD 1.85 billion
Forecast Year [2032] USD 3.22 billion
CAGR (%) 9.69%

A focused orientation to the evolving clinical, regulatory, and commercial context that frames strategic decisions for advanced recurrent ovarian cancer stakeholders

Advanced recurrent ovarian cancer presents a rapidly evolving therapeutic and commercial environment defined by shifting clinical paradigms and intensifying stakeholder scrutiny. This executive summary introduces the core themes of the research, focusing on how advances in targeted modalities, biomarker-driven care, and care delivery models converge to change treatment pathways for patients with recurrent disease. The introduction also frames regulatory pressures, payer expectations, and supply chain considerations that intersect with clinical advances to shape commercial viability.

In addition, the introduction outlines the methodological approach and scope used to examine therapeutic classes, routes of administration, lines of therapy, biomarker-defined subpopulations, care settings, and distribution channels. By establishing a clear problem statement and analytical boundaries, the introduction prepares readers for the deeper analysis that follows, while highlighting the practical implications for development teams, commercial leaders, and investor groups. Ultimately, this section positions the reader to interpret subsequent insights with an understanding of clinical context and stakeholder priorities.

How precision diagnostics, administration route evolution, and payer-driven evidence requirements are reshaping treatment paradigms and commercialization strategies

The therapeutic landscape for advanced recurrent ovarian cancer is undergoing transformative shifts driven by therapeutic innovation, precision diagnostics, and care delivery redesign. Novel targeted therapies and combination regimens are redefining efficacy expectations and tolerability trade-offs, while companion diagnostics and broader adoption of homologous recombination deficiency testing are enabling more individualized treatment selection. As a result, traditional chemotherapy-dominant pathways are being recalibrated in favor of targeted agents and immunotherapy combinations where molecularly appropriate.

Concurrently, payer policies and real-world evidence requirements are prompting manufacturers to integrate health economics and outcomes research earlier in development. This trend increases the premium on robust, longitudinal outcome data and on demonstrating value across multiple lines of therapy. Moreover, the route of administration is becoming a strategic differentiator; therapies that enable oral or subcutaneous delivery offer advantages in patient convenience and outpatient management, thereby affecting adoption and channel preference. Taken together, these shifts require cross-functional alignment among clinical development, diagnostics partnerships, market access, and commercial operations to capture emerging opportunities effectively.

Strategic consequences of 2025 trade-policy shifts on supply chain resilience, procurement practices, and commercial positioning in oncology therapeutics

The introduction of tariffs and trade-policy shifts in 2025 has introduced discrete operational and strategic complexity for stakeholders across the advanced recurrent ovarian cancer ecosystem. Supply chain managers and procurement teams have responded by reassessing sourcing strategies for active pharmaceutical ingredients, finished products, and key diagnostic reagents to mitigate cost volatility and potential delivery delays. As a consequence, firms with vertically integrated supply chains or diversified manufacturing footprints have greater flexibility to absorb near-term tariff impacts, while others are accelerating supplier qualification and contingency planning.

From a commercial perspective, tariff-related cost pressures are increasing scrutiny on price versus value narratives when engaging payers and hospital procurement committees. Manufacturers are therefore prioritizing evidence generation that demonstrates real-world benefits, reductions in downstream resource use, and patient-centered outcomes to sustain favorable formulary positioning. In parallel, distributors and specialty pharmacies have re-evaluated inventory practices and freight optimization to maintain continuity of care for patients on critical therapies. In summary, tariff-driven dynamics have amplified the importance of resilient manufacturing, robust value communication, and proactive supply chain risk management.

Integrated segmentation perspective showing how treatment class, administration route, therapy line, biomarker-defined cohorts, care settings, and distribution channels interact to shape adoption

Segment-level insight reveals how therapeutic decisions, administration preferences, line-of-therapy placement, biomarker status, care settings, and distribution partners collectively shape clinical and commercial trajectories. Based on treatment type, the market spans chemotherapy-where differentiation exists between platinum based agents and non-platinum agents-hormone therapy including aromatase inhibitors and estrogen receptor modulators, immunotherapy comprising cancer vaccines and checkpoint inhibitors, surgery as a critical intervention, and targeted therapy that includes anti-angiogenic agents and PARP inhibitors; each class presents distinct efficacy profiles, tolerability considerations, and evidence-generation needs that influence adoption across clinical practices.

Based on administration route, therapeutic uptake is influenced by the balance between inpatient infusion requirements and the growing preference for oral or subcutaneous options that support outpatient care and patient convenience. Based on line of therapy, strategic positioning varies across fourth and beyond, second line, and third line settings, with organizations tailoring clinical development and sequencing studies to demonstrate meaningful benefit where unmet need and reimbursement potential intersect. Based on biomarker status, differentiation is most apparent in BRCA mutant populations and across homologous recombination deficiency positive and negative subgroups, which drive diagnostic integration and targeted therapy eligibility. Based on end user, adoption dynamics differ among ambulatory care centers, cancer centers, hospitals, and specialty clinics as each setting has unique clinical workflows, budget cycles, and procurement practices. Based on distribution channel, dynamics across hospital pharmacies, online pharmacies, and retail pharmacies affect patient access, channel economics, and adherence support strategies. Integrating these segmentation dimensions uncovers practical implications for clinical development, diagnostics alignment, pricing strategy, and channel-specific commercialization planning.

Regional imperatives and differentiated market entry strategies driven by payer diversity, diagnostic capacity, and regulatory variance across global geographies

Regional dynamics materially influence clinical pathways, regulatory expectations, diagnostic adoption, and commercialization approaches. In the Americas, payer heterogeneity and concentrated specialty pharmacy networks emphasize the importance of health economic evidence and patient support programs to secure coverage and access. In Europe, Middle East & Africa, diverse regulatory environments and reimbursement frameworks mean that market entry strategies must be tailored to national payer criteria and regional centers of excellence, while diagnostic infrastructure and access to molecular testing vary widely across the region. In the Asia-Pacific region, rapid expansion of diagnostic capabilities in certain countries and increasing public investment in oncology care create opportunities for early market entry, though local regulatory and pricing pressures often require adaptive commercialization models.

Consequently, successful regional strategies prioritize early stakeholder mapping, investment in diagnostic partnerships where biomarker-driven therapies matter most, and flexible channel strategies that reflect local distribution and reimbursement realities. Transitional considerations include local evidence generation to support formulary decisions and partnerships with regional clinical leaders to demonstrate real-world utility across diverse healthcare systems.

Competitive positioning shaped by clinical differentiation, diagnostics partnerships, and strategic alliances that enable precise patient targeting and payer engagement

Competitive dynamics in advanced recurrent ovarian cancer are concentrated among multinational pharmaceutical companies, specialized oncology biotechs, diagnostic firms that enable biomarker-guided care, and emerging contract manufacturing and distribution partners. Leading developers differentiate through clinical program design that emphasizes meaningful progression-free and patient-reported outcomes, the pursuit of biomarker-driven label expansions, and investment in companion diagnostics to secure precise patient populations. Biotech innovators frequently pursue combination regimens and novel mechanisms to address resistant disease, while established companies leverage scale, commercial infrastructure, and global regulatory experience to accelerate launch readiness.

Collaborations and licensing arrangements between therapeutic developers and diagnostic companies have become pivotal, enabling synchronized regulatory submissions and payer narratives. In addition, strategic alliances with specialty pharmacy networks and hospital systems support adherence programs and optimize channel-level distribution. Accordingly, companies that align clinical differentiation with a coherent diagnostics and access strategy will be better positioned to navigate complex reimbursement pathways and deliver sustained uptake in clinically appropriate patient cohorts.

Practical strategic steps industry leaders can implement to integrate diagnostics, bolster evidence generation, fortify supply chains, and accelerate payer acceptance across markets

Industry leaders should prioritize a set of actionable initiatives to capture therapeutic and commercial opportunities while mitigating risk. First, integrate biomarker strategy into clinical development from first-in-human through label-expansion studies to ensure timely companion-diagnostic availability and clear patient selection criteria. Second, invest in real-world evidence generation and health economics research early to support payer conversations and to demonstrate downstream value beyond traditional efficacy endpoints. Third, design development programs to consider administration route as a commercial differentiator, evaluating oral or subcutaneous formulations where clinically feasible to support outpatient care and adherence.

Furthermore, companies should strengthen supply chain resilience by diversifying sourcing, qualifying multiple manufacturing partners, and maintaining transparent logistics contingency plans to limit exposure to tariff or trade-policy disruptions. Establishing strong relationships with specialty pharmacies, hospital systems, and ambulatory care networks will facilitate access programs and channel-specific patient support. Finally, adopt a data-driven market access playbook that aligns evidence generation, pricing strategy, and stakeholder engagement across targeted regions to accelerate adoption and manage payer expectations effectively.

A transparent mixed-methods research approach combining primary expert insights, rigorous secondary source validation, and scenario analysis to ensure actionable findings

The research methodology underpinning this report integrates primary qualitative interviews with clinical experts, payers, and commercialization leaders, secondary literature review across peer-reviewed journals and regulatory documents, and structured synthesis of diagnostic and therapeutic pipelines. Primary input included semi-structured interviews with oncology clinicians, hospital pharmacists, and market access specialists to validate clinical pathways, identify adoption barriers, and surface payer evidence priorities. Secondary research encompassed regulatory guidance documents, clinical trial registries, and published outcome studies to corroborate therapeutic efficacy, safety profiles, and diagnostic utility.

Data synthesis applied triangulation methods to reconcile divergent perspectives and to distill practical implications for development and commercialization. The methodology also incorporated scenario analysis to explore supply chain and policy contingencies and expert validation rounds to ensure interpretive rigor. Transparency of assumptions and a documented audit trail of sources support reproducibility and enable clients to align the findings with internal evidence and strategic planning processes.

Consolidated insights emphasizing diagnostic-driven personalization, evidence-aligned development, and supply chain resilience as pillars for sustained commercial success

In conclusion, the advanced recurrent ovarian cancer ecosystem is at an inflection point where diagnostic-led personalization, therapeutic innovation, and payer-driven evidence demands intersect to reshape clinical and commercial pathways. Stakeholders that proactively integrate biomarker strategies, prioritize evidence generation aligned with payer needs, and optimize delivery models that favor patient-centric administration options will gain competitive advantage. Moreover, resilience in supply chain design and adaptive regional strategies are essential to navigate policy-related cost pressures and heterogeneous reimbursement landscapes.

Ultimately, the synthesis presented here should guide clinical development prioritization, commercialization sequencing, and cross-functional alignment to capture sustainable value. Decision-makers can use these insights to refine go-to-market plans, focus investment in high-impact evidence generation, and build partnerships that enhance diagnostic-enabled patient identification and access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Advanced Recurrent Ovarian Cancer Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Non-Platinum Agents
    • 8.1.2. Platinum Based Agents
  • 8.2. Hormone Therapy
    • 8.2.1. Aromatase Inhibitors
    • 8.2.2. Estrogen Receptor Modulators
  • 8.3. Immunotherapy
    • 8.3.1. Cancer Vaccines
    • 8.3.2. Checkpoint Inhibitors
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Anti Angiogenic Agents
    • 8.5.2. Parp Inhibitors

9. Advanced Recurrent Ovarian Cancer Market, by Administration Route

  • 9.1. Intraperitoneal
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Advanced Recurrent Ovarian Cancer Market, by Line Of Therapy

  • 10.1. Fourth And Beyond
  • 10.2. Second Line
  • 10.3. Third Line

11. Advanced Recurrent Ovarian Cancer Market, by Biomarker Status

  • 11.1. Homologous Recombination Deficiency Negative
  • 11.2. Homologous Recombination Deficiency Positive

12. Advanced Recurrent Ovarian Cancer Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Cancer Centers
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Advanced Recurrent Ovarian Cancer Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Advanced Recurrent Ovarian Cancer Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Advanced Recurrent Ovarian Cancer Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Advanced Recurrent Ovarian Cancer Market

17. China Advanced Recurrent Ovarian Cancer Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Celsion Corporation
  • 18.12. Clovis Oncology Inc.
  • 18.13. Debiopharm International SA
  • 18.14. Eli Lilly and Company
  • 18.15. Exelixis Inc.
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Genentech Inc.
  • 18.18. GlaxoSmithKline plc
  • 18.19. ImmunoGen Inc.
  • 18.20. Johnson & Johnson Services, Inc.
  • 18.21. Kintara Therapeutics Inc.
  • 18.22. Merck & Co., Inc.
  • 18.23. Mirati Therapeutics Inc.
  • 18.24. Novartis AG
  • 18.25. Pfizer Inc.
  • 18.26. Regeneron Pharmaceuticals Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Takeda Pharmaceutical Company Limited
  • 18.29. Vivesto AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)